OneSource Specialty Pharma Ltd
OneSource Specialty Pharma Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Significant revenue growth expected driven by multiple MSA executions and capacity expansions (Page 8). Q2 FY26 showed strong revenue growth and a 37% rise in EBITDA with a 500+ bps margin expansion.
From OneSource Specialty Pharma Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Significant revenue growth expected driven by multiple MSA executions and capacity expansions (Page 8).
- Accelerated capacity expansion to 220 million units by end of CY 2026 to support anticipated demand (Pages 9, 16).
- Expectation of eight to ten customers launching products globally in FY 2027 boosting commercial supply (Page 6).
- Current capacity utilization is uncertain but expected to increase in phases through 2026 (Page 18).
- Customers involved in capacity capex and reservation fees indicating strong demand and long-term partnerships (Pages 10, 16).
- Confidence in capturing customer demand as capacity added progressively in phases through calendar year 2026 (Page 18).
2 more points from OneSource Specialty Pharma Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what OneSource Specialty Pharma Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- OneSource Specialty Pharma is actively accelerating its Phase 2 capacity expansion to support FY ’27 commercialization plans for the DDC (drug-device combination) business.
- The company is investing significantly in capital expansion, evidenced by increased net debt and prepaid high-cost debt to maintain financial discipline.
- Capacity additions are planned in phases through calendar year 2026, including expansions by May/June, September/October, and end of year.
- There is also an intention to expand biologics capacity beyond the current 4 kL installed, with plans to almost double it to 8 kL through limited capex.
- Future capacity expansions outside India are being considered, with Warsaw operations cited as a potential site for next expansion.
2 more points from OneSource Specialty Pharma Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what OneSource Specialty Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The order book for OneSource Specialty Pharma Limited's drug-device combination segment remains solid.
- Nearly 8 to 10 customers are expected to launch products across multiple global markets in the next year, driving growth.
- The company has 50+ active RFPs (Request for Proposals) across various modalities, including soft gelatin, injectables, and biologics, indicating a healthy pipeline.
- The company continues to receive new customer engagements, including licensing agreements and MSAs.
- Customers are actively participating in capital expenditure plans to secure capacity, reflecting committed demand.
- Working capital is elevated due to planned inventory buildup for future DDC launches, backed by customer advances and purchase orders.
2 more points from OneSource Specialty Pharma Ltd's call on order book
Pro opens every point from 15K+ earnings calls
OneSource Specialty Pharma Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹428 Cr, net profit ₹5 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What OneSource Speci.'s management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Bajaj Healthcare (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p
- Infinium Pharma (Q2 FY26)
Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium
- Wanbury (Q2 FY26)
Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q2 FY26)
Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee
Arthneeti Pro · Annual
OneSource Specialty Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were OneSource Specialty Pharma Ltd Q2 FY26 results?
Significant revenue growth expected driven by multiple MSA executions and capacity expansions (Page 8). Q2 FY26 showed strong revenue growth and a 37% rise in EBITDA with a 500+ bps margin expansion.
What is OneSource Specialty Pharma Ltd share price analysis?
OneSource Specialty Pharma Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹17,817 Cr. Investors should review the full earnings analysis for detailed insights.
Is OneSource Specialty Pharma Ltd planning capital expenditure?
OneSource Specialty Pharma is actively accelerating its Phase 2 capacity expansion to support FY ’27 commercialization plans for the DDC (drug-device combination) business.
Keep OneSource Specialty Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.